Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BLESS III: LetibotulinumtoxinA for Glabellar Lines
NCT03985982Phase 3Completed
- Sponsor
- Croma-Pharma
- Start
- Apr 2019
- Primary completion
- Dec 2019
- Modality
- Therapeutic Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of letibotulinumtoxinA in glabellar lines (3 arms), sponsored by Croma-Pharma. Primary endpoint: Facial Wrinkle Scale (FWS) Score of 0 or 1 and an Improvement of ≥ 2 Points in FWS Score (at Maximum Frown) at Week 4. Started Apr 2019; status: completed.
02
Drugs
letibotulinumtoxinA
03
Conditions
glabellar lines
Beyond the preview
Go deeper on NCT03985982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03985982.